Genmab — December 2019
-
CANDOR study: should Dara-Kd become the new SOC for len refractory patients with RRMM? https://www.youtube.com/watch?v=Yhj_rwxWt60
-
Thanks E L. I have put your link in the debat: https://www.proinvestor.com/index.php?p=debat_1&postid=80141
-
it is the curse of investing in a stock that you follow so close fundamentaly and you have a strong opinion on... Even after watching this stock this long, with all its uncontrolled and irrational up- and dows, unconsciously we still think it should trade according to our -admittedly pretty well informed- opinion...
-
The market is irrational, but the fundamentals tend to win in the long run.
-
The irrational element arises because the market participants have different strategies, motives and time horizons. If all Genmab investors were patient and long-term, there would never be any shares for sale.:-)
-
SAC Tracker
@FDAadcomm
FDA ADCOMM VOTE: Do the potential benefits of using #teprotumumab as recommended outweigh the potential risks associated with the use of the drug product for the intended population?
12-Yes
0-No
0-Abstain
Horizon Therapeutics, proposed use for active thyroid eye disease $HZNP -
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind